LACY HOSAY: Open Payments
NPI 1538683636 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,325 in 77 payments from 20 companies in 2025. Trend: 2023 $2,361 · 2024 $1,517 · 2025 $1,325
Food & beverage: $1,325
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $532 |
| AstraZeneca Pharmaceuticals LP | 9 | $162 |
| Novo Nordisk Inc | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Amgen Inc. | 3 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $42 |
| PFIZER INC. | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| GlaxoSmithKline, LLC. | 2 | $32 |
Products named: VRAYLAR, UBRELVY, QULIPTA, CAPLYTA, AIRSUPRA, REXULTI, Wegovy, XIFAXAN.
Industry payments across MO — which companies pay providers there.
